Get started
Author

Stefano Ferrara

Adjuvant nab -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial
2022 · Margaret A. Tempero, Uwe Pelzer, et al. · Journal of Clinical Oncology · 146
PDF
APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma.
2019 · Margaret A. Tempero, Michele Reni, et al. · Journal of Clinical Oncology · 142
Prognostic Factors of Survival in a Randomized Phase III Trial (MPACT) of Weekly nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer
2015 · Josep Tabernero, E. Gabriela Chiorean, et al. · The Oncologist · 138
PDF
Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: A subset analysis from a randomised phase III trial (MPACT)
2015 · David Goldstein, Daniel D. Von Hoff, et al. · European Journal of Cancer · 52
PDF
Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer
2018 · Lucas Moreno, Michela Casanova, et al. · European Journal of Cancer · 32
Tumor Reduction in Primary and Metastatic Pancreatic Cancer Lesions With nab-Paclitaxel and Gemcitabine
2016 · Volker Kunzmann, Ramesh K. Ramanathan, et al. · Pancreas · 26
nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: a subgroup analysis of the Western European cohort of the MPACT trial
2017 · Josep Tabernero, Volker Kunzmann, et al. · OncoTargets and Therapy · 25
PDF
nab‐Paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: Australian subset analyses of the phase III MPACT trial
2018 · Rosemary Young, Paul Mainwaring, et al. · Asia-Pacific Journal of Clinical Oncology · 5
Tumor reduction in pancreatic versus metastatic sites in a randomized phase III study (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone.
2015 · Volker Kunzmann, Ramesh K. Ramanathan, et al. · Journal of Clinical Oncology · 1
Regional Subanalysis of the Phase III Mpact Trial: Nab-Paclitaxel (Nab-P) Plus Gemcitabine (Gem) Vs Gem Alone for Patients (Pts) with Metastatic Pancreatic Cancer (Pc)
2014 · S. Siena, L. Lipton, et al. · Annals of Oncology · 1
Nab-Paclitaxel Plus Gemcitabine Vs Gemcitabine Alone for Patients with Metastatic Pancreatic Cancer: Influence of Primary Pancreatic Tumor Location on Efficacy and Treatment Exposure in the Mpact Phase III Trial
2014 · Lopez-Martin Jose, Ma Wen Wee, et al. · Annals of Oncology · 1
PDF
Phase III, international, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + G) versus gemcitabine (G) for resected pancreatic cancer (APACT): Recurrence patterns.
2020 · Vaibhav Sahai, Josep Tabernero, et al. · Journal of Clinical Oncology
Reduction in primary pancreatic and metastatic tumor burden in the phase III MPACT trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone.
2015 · Volker Kunzmann, Ramesh K. Ramanathan, et al. · Journal of Clinical Oncology
Influence of Primary Pancreatic Tumor Location on Efficacy and Treatment Exposure in the Mpact Trial of Nab-Paclitaxel (Nab-P) Plus Gemcitabine (Gem) Vs Gem Alone for Patients with Metastatic Pancreatic Cancer (Mpc)
2014 · W.W. Ma, J.A. López-Martín, et al. · Annals of Oncology
Works count: 14
Citation count: 569
H-index: 7
I10-index: 7
Year
Topic
Type